SLC1A5 and neoplasm: One study demonstrated that apatinib inhibited the expression of GLS1, activated the GCN2/eIF2α/ATF4 pathway, and promoted the expression of SLC1A5, thereby reprogramming Gln metabolism in NSCLC and weakening the response of tumor cells to apatinib (33).